Atrial Fibrillation

  • J. Anthony GomesEmail author


Atrial fibrillation (AF) is the commonest arrhythmia seen in clinical practice and is responsible for thromboembolic strokes, substantial impairment in life quality, and mortality. This chapter discusses the epidemiology of AF, the different types of AF, and its mechanisms and treatment including stroke prevention and rate and rhythm control with special reference to current and future catheter ablation strategies.


Atrial fibrillation Paroxysmal Persistent Pulmonary veins Rotors Vagal atrial fibrillation Stroke prevention Rate control Rhythm control Ablation 


  1. 1.
    Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.PubMedGoogle Scholar
  2. 2.
    Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural, history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371–8.PubMedGoogle Scholar
  3. 3.
    Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–41.PubMedGoogle Scholar
  4. 4.
    Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476–84.PubMedGoogle Scholar
  5. 5.
    Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Ohnsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.PubMedGoogle Scholar
  6. 6.
    Wolf PA, Abbott RD, Kannel WB. Atrial’ fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.PubMedGoogle Scholar
  7. 7.
    Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–18.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–4.PubMedGoogle Scholar
  9. 9.
    Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation. 2004;110:1042–6.PubMedGoogle Scholar
  10. 10.
    Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121–6.PubMedGoogle Scholar
  11. 11.
    Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348–56.PubMedGoogle Scholar
  12. 12.
    Clark DM, Plumb VJ, Epstein AB, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039–45.PubMedGoogle Scholar
  13. 13.
    Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709–15.PubMedGoogle Scholar
  14. 14.
    van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail. 2006;8:539–46.PubMedGoogle Scholar
  15. 15.
    De Ferrari GM, Klersy C, Ferrero P, et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007;9:502–9.PubMedGoogle Scholar
  16. 16.
    Corell P, Gustafsson F, Schou M, Markenvard J, Nielsen T, Hildebrandt P. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail. 2007;9:258–65.PubMedGoogle Scholar
  17. 17.
    Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997–2004.PubMedGoogle Scholar
  18. 18.
    Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548–57.PubMedGoogle Scholar
  19. 19.
    Swedberg K, Olsson LG, Charlesworth A, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26:1303–8.PubMedGoogle Scholar
  20. 20.
    Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–9.PubMedGoogle Scholar
  21. 21.
    Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.Google Scholar
  22. 22.
    Ott A, Breteler MM, de Brune MC, et al. Atrial fibrillation in a population based study. The Rotterdam Study. Stroke. 1997;28(2):316–21.PubMedGoogle Scholar
  23. 23.
    de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55(8):725–3.PubMedGoogle Scholar
  24. 24.
    Proietti R, Hadjis A, AlTurki A, et al. A systematic review on the progression of paroxysmal to persistent atrial fibrillation: shedding new light on the effects of catheter ablation. J Am Coll Cardiol. 2015;1:105–15.Google Scholar
  25. 25.
    Frustaci A, Caldarulo M, Buffon A, et al. Cardiac biopsy in patients with “primary” atrial fibrillation histologic evidence of occult myocardial diseases. Chest. 1991;100(2):303–6.PubMedGoogle Scholar
  26. 26.
    Frustaci A, Cameli SO, Zeppilli P. Biopsy evidence of atrial myocarditis in an athlete developing transient sinoatrial disease. Chest. 1995;108:1460–2.PubMedGoogle Scholar
  27. 27.
    Coumel P, Attuel P, Lavallee J, Flammang D, Leclercq JF, Slama R. The atrial arrhythmia syndrome of vagal origin. Arch Mal Coeur Vaiss. 1978;71:645–56.PubMedGoogle Scholar
  28. 28.
    de Vos CB, Nieuwlaat R, Crijns HJ, et al. Autonomic trigger patterns and anti-arrhythmic treatment of paroxysma atrial fibrillation: data from the Euro Heart Survey. Eur Heart J. 2008;29:632–9.PubMedGoogle Scholar
  29. 29.
    Rosso R, Sparks PB, Morton JB, et al. Vagal paroxysmal atrial fibrillation: prevalence and ablation outcome in patients without structural heart disease. J Cardiovasc Electrophysiol. 2010;21:489–93.PubMedGoogle Scholar
  30. 30.
    Oral H, Chugh A, Scharf C, et al. Pulmonary vein isolation for vagotonic, adrenergic and random episodes of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2004;15:402–6.PubMedGoogle Scholar
  31. 31.
    Niemerovsky D, Hutter R, Gomes JA. The electrical substrate of vagal atrial fibrillation as assessed by the signal-averaged electrocardiogram. Pacing Clin Electrophysiol. 2008;31:308–13.Google Scholar
  32. 32.
    Patterson E, Po SS, Scherlag BJ, et al. Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation. Heart Rhythm. 2005;2:624–31.PubMedGoogle Scholar
  33. 33.
    Lemola K, Chartier D, Yeh YH, et al. Pulmonary vein region ablation in experimental vagal atrial fibrillation: role of pulmonary veins versus autonomic ganglia. Circulation. 2008;117:470–7.PubMedGoogle Scholar
  34. 34.
    Sharifov OF, Fedorov VV, Beloshapko GG, et al. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol. 2004;43:483–90.PubMedGoogle Scholar
  35. 35.
    Winterberg H. Studien über Herzflimmern. I. Über die Wirkung des Nvagus un accelerans auf das Flimmern des Herzens. Pflugers Arch Ges Physiol. 1907;117:223–56.Google Scholar
  36. 36.
    Lewis T. The mechanism and graphic registration of the heart beat. 3rd ed. London: Shaw & Sons; 1925. p. 319–74.Google Scholar
  37. 37.
    Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58:59–70.PubMedGoogle Scholar
  38. 38.
    Allessie MA, Lammers WEJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe’s multiple wavelet hypothesis of atrial fibrillation. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology and arrhythmias. Orlando: Grune & Stratton; 1985. p. 265–75.Google Scholar
  39. 39.
    Lee S, Sahadevan J, Celeen M, et al. High density mapping of atrial fibrillation during vagal nerve stimulation in the canine heart: restudying the Moe hypothesis. J Cardiovasc Electrophysiol. 2013;24:328–35.PubMedGoogle Scholar
  40. 40.
    Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins. An anatomic study of human hearts. Circulation. 1966;34:412–22.PubMedGoogle Scholar
  42. 42.
    Nattel S, Heijman J, Voigt N, et al. The molecular pathophysiology of atrial fibrillation. In: Zipes DP, editor. Cardiac electrophysiology: from cell to bedside. Philadelphia: Elsevier Health Sciences; 2015.Google Scholar
  43. 43.
    Jalife J. Rotors and spiral waves in atrial fibrillation. J Cardiovasc Electrophysiol. 2003;14:776–80.PubMedGoogle Scholar
  44. 44.
    Santoni-Rugiu F, Verma R, Mehta D, Gopal A, Chan EKY, Pe E, Gomes JA. Signal averaged P-wave discrimates between persistent and paroxysmal atrial fibrillation. J Electrocardiol. 2001;34:189–95.PubMedGoogle Scholar
  45. 45.
    Chalfoun N, Harnick D, Pe E, Undavia M, Mehta D, Gomes JA. Reverse electrical remodeling of the atria post cardioversion in patients who remain in sinus rhythm. Assessed by signal averaging of the P-wave. Pacing Clin Electrophysiol. 2007;30:502.PubMedGoogle Scholar
  46. 46.
    van der Velden HMW, Jongsma HJ. Cardiac gap junctions and connexins: their role in atrial fibrillation and potential as therapeutic targets. Cardiovasc Res. 2002;54:270–9.PubMedGoogle Scholar
  47. 47.
    van der Velden HM, van Kempen MJ, Groenewegen WA, Jongsma IHJ. Comparative analysis of the distribution of the gap junction proteins connexins 40 and 43 in chronic atrial fibrillation (AF). Circulation. 1997;96(8):237, Dent Abstr.Google Scholar
  48. 48.
    Sun H, Gaspo R, Leblanc N, Nattel S. Cellular mechanisms of atrial contractile dysfunction caused by sustained atrial tachycardia. Circulation. 1998;98(7):719–27.PubMedGoogle Scholar
  49. 49.
    Schotten U, Ausma J, Stellbrink C, et al. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 2001;103(5):691–8.PubMedGoogle Scholar
  50. 50.
    van der Velden HM, Ausma J, Van Ankeren EP, Jongsma HJ. Recovery of gap junctional remodeling after cardioversion of chronic atrial fibrillation in the goat. Pacing Clin Electrophysiol. 2001;24(4):596, Abstract.Google Scholar
  51. 51.
    Spach MS, Starmer CF. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res. 1995;30(3):337–44.PubMedGoogle Scholar
  52. 52.
    Tieleman RG, van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31(1):167–73.PubMedGoogle Scholar
  53. 53.
    Brundel BJ. Molecular adaptations in human atrial fibrillation: mechanisms of protein remodeling. Groningen: University of Groningen; 2000.Google Scholar
  54. 54.
    Wolff L. Familial auricular fibrillation. N Engl J Med. 1943;229:396–8.Google Scholar
  55. 55.
    Fox CS, Parise H, D’Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291:2851–5.PubMedGoogle Scholar
  56. 56.
    Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet. 2005;118:179–84.PubMedGoogle Scholar
  57. 57.
    Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304:2263–9.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. Circ Res. 2014;114:1469–82.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Christophersen IE, Ravn LS, Budtz-Joergensen E, et al. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol. 2009;2:378–83.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353–7.PubMedGoogle Scholar
  61. 61.
    Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009;2:4.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Wustmann K, Kucera JP, Zanchi A, et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. Endocrinol Metab. 2008;93:2104–8.Google Scholar
  63. 63.
    Michelson EL, Morganroth J, MacVaugh H III. Postoperative arrhythmias after coronary artery and cardiac valvular surgery detected by long-term electrocardiographic monitoring. Am Heart J. 1979;97:442–8.PubMedGoogle Scholar
  64. 64.
    Ormerod OJM, McGregor CGA, Stone DL, et al. Arrhythmias after coronary bypass surgery. Br Heart J. 1984;51:618–21.PubMedPubMedCentralGoogle Scholar
  65. 65.
    White HD, Antman EM, Glynn MA, et al. Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias aftercoronary artery bypass surgery. Circulation. 1984;70:479–84.PubMedGoogle Scholar
  66. 66.
    Rubin DA, Nieminski KE, Reed GE, Herman MV. Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations. J Thorac Cardiovasc Surg. 1987;94:331–5.PubMedGoogle Scholar
  67. 67.
    Fuller JA, Adams GG, Buxton B. Atrial fibrillation after coronaryartery bypass grafting: is it a disorder of the elderly? J Thorac Cardiovasc Surg. 1989;97:821–5.PubMedGoogle Scholar
  68. 68.
    Lauer MS, Eagle KA, Buckley MJ, DeSanctis RW. Atrial fibrillation following coronary artery bypass surgery. Prog Cardiovasc Dis. 1989;31:367–78.PubMedGoogle Scholar
  69. 69.
    Leitch JW, Thomson D, Baird DK, Harris PJ. The importance of age as a predictor of atrial fibrillation and flutter after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1990;100:338–42.PubMedGoogle Scholar
  70. 70.
    Carreta Q, Mercanti CA, De Nardo D, et al. Ventricular conduction defects and atrial fibrillation after coronary artery bypass grafting: multivariate analysis of preoperative, intraoperative and postoperative variables. Eur Heart J. 1991;12:1107–11.Google Scholar
  71. 71.
    Crosby LH, Pifalo WB, Woll KR, Burkholder JA. Risk factors for atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 1990;66:1520–2.PubMedGoogle Scholar
  72. 72.
    Yousif H, Davies G, Oakley CM. Peri-operative supraventricular arrhythmias in coronary bypass surgery. Int J Cardiol. 1990;26:313–8.PubMedGoogle Scholar
  73. 73.
    Parikka H, Toivonen L, Pellinen T, et al. The influence of intravenous magnesium sulphate on the occurrence of atrial fibrillation aftercoronary artery bypass operation. Eur Heart J. 1993;14:251–8.PubMedGoogle Scholar
  74. 74.
    Cox JL. A perspective of postoperative atrial fibrillation in cardiac operations. Ann Thorac Surg. 1993;56:405–9.PubMedGoogle Scholar
  75. 75.
    Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery: current trends and impact on hospital resources. Circulation. 1996;94:390–7.PubMedGoogle Scholar
  76. 76.
    Parikka H, Toivonen L, Heikkila K, et al. Comparison of sotalol and metoprolol in the prevention of atrial fibrillation after coronary artery bypass surgery. J Cardiovasc Pharmacol. 1998;31:67–73.PubMedGoogle Scholar
  77. 77.
    Kowey PR, Taylor JE, Rials SJ, Marinchak RA. Meta-analysis of the effectiveness of prophylactic drug therapy in preventing supraventricular arrhythmia early after coronary bypass surgery. Am J Cardiol. 1992;69:963–5.PubMedGoogle Scholar
  78. 78.
    Andrews TC, Reimold SC, Berlin JA, Antman EM. Prevention of supra-ventricular arrhythmias after coronary artery bypass surgery: a meta-analysis of randomized controlled trials. Circulation. 1991;84(Suppl III):236–44.Google Scholar
  79. 79.
    Ivey MF, Ivey TD, Bailey WW, et al. Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization:a randomized trial. J Thorac Cardiovasc Surg. 1983;85:214–8.PubMedGoogle Scholar
  80. 80.
    Martinussen HJ, Lolk A, Szczepanski C, Alstrup P. Supraventricular tachyarrhythmias after coronary bypass surgery—a double-blind randomized trial of prophylactic low-dose propranolol. Thorac Cardiovasc Surg. 1988;36:206–7.PubMedGoogle Scholar
  81. 81.
    Shafei H, Nashef SA, Turner MA, Bain WH. Does low-dose propranolol reduce the incidence of supraventricular tachyarrhythmias following myocardial revascularization? A clinical study. Thorac Cardiovasc Surg. 1988;36:202–5.PubMedGoogle Scholar
  82. 82.
    Laub GW, Janeira L, Muralidharan S, et al. Prophylactic procainamide for the prevention of atrial fibrillation after coronary artery bypass grafting: a prospective double-blind, randomized, placebocontrolled pilot study. Crit Care Med. 1993;21:1474–8.PubMedGoogle Scholar
  83. 83.
    McCarty RJ, Jahnke EJ, Walker WJ. Ineffectiveness of quinidine in preventing atrial fibrillation following mitral valvotomy. Circulation. 1966;34:792–4.PubMedGoogle Scholar
  84. 84.
    Merrick AF, Odom MJ, Keenan DJM, Grotte GJ. Comparison of propafenone to atenolol for the prophylaxis of post cardiotomy supraventricular tachyarrhythmias: a prospective trial. Eur J Cardiothorac Surg. 1995;9:146–9.PubMedGoogle Scholar
  85. 85.
    Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J. 1991;121:89–95.PubMedGoogle Scholar
  86. 86.
    Daoud EG, Strickberger SA, Mau KC, et al. Properative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med. 1997;337:1785–91.PubMedGoogle Scholar
  87. 87.
    Mickleborough LL, Maruyama H, Mahamad S, et al. Are patients receiving amiodarone at increased risk for cardiac operations? Ann Thorac Surg. 1994;58:622–9.PubMedGoogle Scholar
  88. 88.
    Gomes JA, Ip J, Santoni-Rugiu F, et al. Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999;34:334–9.PubMedGoogle Scholar
  89. 89.
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–e76.PubMedGoogle Scholar
  90. 90.
    Grigioni F, Avierinos J-F, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation determinants and long-term outcome. J Am Coll Cardiol. 2002;40:84–92.PubMedGoogle Scholar
  91. 91.
    Boyden PA, Tilley LP, Pham TD, Liu SK, Fenoglio JJ Jr, Wit AK. Effects of left atrial enlargement on atrial transmembrane potentials and structure in dogs with mitral valve fibrosis. Am J Cardiol. 1982;49:1896–908.PubMedGoogle Scholar
  92. 92.
    Fukada J, Morishita K, Komatsu K, et al. Is atrial fibrillation resulting from rheumatic mitral valve disease a proper indication for the maze procedure? Ann Thorac Surg. 1998;65:1566–9.PubMedGoogle Scholar
  93. 93.
    Cox JL, Schuessler RB, Boineau JP. The development of the mazeprocedure for the treatment of atrial fibrillation. Semin Thorac Cardiovasc Surg. 2000;12:2–14.PubMedGoogle Scholar
  94. 94.
    Cox JL. Intraoperative options for treating atrial fibrillation associated with mitral valve disease. J Thorac Cardiovasc Surg. 2001;122:212–5.PubMedGoogle Scholar
  95. 95.
    Ad N, Cox JL. Combined mitral valve surgery and the Maze III procedure. Semin Thorac Cardiovasc Surg. 2002;14:206–9.PubMedGoogle Scholar
  96. 96.
    Gillinov AM, Sirak J, Blackstone EH, et al. The Cox maze procedure in mitral valve disease: predictors of recurrent atrial fibrillation. J Thorac Cardiovasc Surg. 2005;130:1653–60.PubMedGoogle Scholar
  97. 97.
    Lee JW, Park NH, Choo SJ, et al. Surgical outcome of the maze procedure for atrial fibrillation in mitral valve disease: rheumatic versus degenerative. Ann Thorac Surg. 2003;75:57–61.PubMedGoogle Scholar
  98. 98.
    Loardi C, Alamanni F, Veglia F, et al. Modified maze procedure for atrial fibrillation as an adjunct to elective cardiac surgery: predictors of mid-term recurrence and echocardiographic follow-up. Tex Heart Inst J. 2015;42(4):341–7.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Saint LL, Bailey MS, Prasad S, et al. Cox-maze IV results for patients with lone atrial fibrillation versus concomitant mitral disease. Ann Thorac Surg. 2012;93(3):789–95.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.PubMedGoogle Scholar
  101. 101.
    January CT, Samuel Wann L, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–32. Scholar
  102. 102.
    Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006–10.PubMedGoogle Scholar
  103. 103.
    Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–12.PubMedGoogle Scholar
  104. 104.
    Hart G, Benavente O, Mc Bride R, Pierce LA. Antithrombotic therapy to prevent strokes in atrial fibrillation. Ann Inter Med. 1999;131(7):492–50.Google Scholar
  105. 105.
    Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.PubMedGoogle Scholar
  106. 106.
    Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.PubMedGoogle Scholar
  107. 107.
    Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.PubMedGoogle Scholar
  108. 108.
    Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol. 2008;141:757–63.PubMedGoogle Scholar
  109. 109.
    Hollowell J, Ruigómez A, Johansson S, et al. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Br J Gen Pract. 2003;53:312–4.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.PubMedGoogle Scholar
  111. 111.
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.Google Scholar
  112. 112.
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.Google Scholar
  113. 113.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.Google Scholar
  114. 114.
    Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:1–18, Article ID 640723.Google Scholar
  115. 115.
    Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–29.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597–605.PubMedGoogle Scholar
  117. 117.
    Lafuente-Lafuente C, Mouly S, Longas-Tejero MA. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719–28.PubMedGoogle Scholar
  118. 118.
    Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.PubMedGoogle Scholar
  119. 119.
    Hohnloser SH, Crijns HJ, van Eickels M, et al. Dronedarone in patients with congestive heart failure: insights from ATHENA. Eur Heart J. 2010;31:1717–21.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.PubMedGoogle Scholar
  121. 121.
    Cox JL, Schuessler RB, D’Agostino HJ Jr, et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg. 1991;101:569–83.PubMedGoogle Scholar
  122. 122.
    Jaïs P, Weerasooriya R, Shah DC, et al. Ablation therapy for atrial fibrillation (AF): past, present and future. Cardiovasc Res. 2002;54:337–46.PubMedGoogle Scholar
  123. 123.
    Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation. 2000;102:2619–28.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Pappone C, Oreto G, Rosanio S, et al. Atrial electro-anatomic remodelling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001;104:2539–44.PubMedGoogle Scholar
  125. 125.
    Arentz T, Weber R, Burkle G, et al. Small or large isolation areas around the pulmonary veins for the treatment of atrial fibrillation? Results from a prospective randomized study. Circulation. 2007;115:3057–63.PubMedGoogle Scholar
  126. 126.
    Oral H, Scharf C, Chugh C, et al. Catheter ablation for paroxysmal atrial fibrillation segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation. 2003;108:2355–60.PubMedGoogle Scholar
  127. 127.
    Karch MR, Zrenner B, Deisenhofer I, et al. Freedom from atrial tachyarrhythmias catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation. 2005;111:2875–80.PubMedGoogle Scholar
  128. 128.
    Miller MA, d’Avila A, Dukkipati SR, et al. Acute electrical isolation is a necessary but insufficient endpoint for achieving durable PV isolation: the importance of closing the visual gap. Europace. 2012;14:653–60.PubMedGoogle Scholar
  129. 129.
    Darby AE. Recurrent atrial fibrillation after catheter ablation: considerations for repeat ablation and strategies to optimize success. J Atr Fibrillation. 2016;9(1):1427.PubMedPubMedCentralGoogle Scholar
  130. 130.
    Kuck KH, Reddy VY, Schmidt B, et al. A novel radiofrequency ablation catheter using contact force sensing: toccata study. Heart Rhythm. 2012;9:18–23.PubMedGoogle Scholar
  131. 131.
    Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004;43:2044–53.PubMedGoogle Scholar
  132. 132.
    Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372:1812–22.Google Scholar
  133. 133.
    Viles-Gonzalez JF, Anthony Gomes J, Miller MA, et al. Areas with complex fractionated atrial electrograms recorded after pulmonary vein isolation represent normal voltage and conduction velocity in sinus rhythm. Europace. 2013;15:339–46.PubMedGoogle Scholar
  134. 134.
    Berenfeld O, Zaitsev AV, Mironov SF, et al. Frequency-dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. Circ Res. 2002;90:1173–80.PubMedGoogle Scholar
  135. 135.
    Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. J Cardiovasc Electrophysiol. 2012;23:447–54. 35.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Narayan SM, Patel J, Mulpuru S, et al. Focal impulse and rotor modulation ablation of sustaining rotors abruptly terminates persistent atrial fibrillation to sinus rhythm with elimination on follow-up: a video case study. Heart Rhythm. 2012;9:1436–9.PubMedPubMedCentralGoogle Scholar
  137. 137.
    Benharash P, Buch E, Frank P, et al. Quantitative analysis of localized sources identified by focal impulse and rotor modulation mapping in atrial fibrillation. Circ Arrhythm Electrophysiol. 2015;8:554–61.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Rudy Y, Messinger-Rapport BJ. The inverse problem in electrocardiography: solutions in terms of epicardial potentials. Crit Rev Biomed Eng. 1987;16:215–68. 79.Google Scholar
  139. 139.
    Cuculich PS, Wang Y, Lindsay BD, et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation. 2010;122:1364–72.PubMedPubMedCentralGoogle Scholar
  140. 140.
    Haïssaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. Circulation. 2014;130:530–8.PubMedGoogle Scholar
  141. 141.
    Hussein AA, Saliba WI, Barakat A, et al. Radiofrequency ablation of persistent atrial fibrillation diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol. 2016;9:e003669. Scholar
  142. 142.
    Bonanno C, Paccanaro M, La Vecchia L, et al. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials. J Cardiovasc Med (Hagerstown). 2010;11:408–18.Google Scholar
  143. 143.
    Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–8.PubMedGoogle Scholar
  144. 144.
    Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation. The CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74. Scholar
  145. 145.
    Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation a randomized controlled trial. JAMA. 2010;303(4):333–40.PubMedGoogle Scholar
  146. 146.
    Packer DL, Kowal RC, Wheelan KR, et al. A clinical study of the Arctic Front cryoablation balloon for the treatment of paroxysmal atrial fibrillation [Stop AF]. First results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61:1713–23.PubMedGoogle Scholar
  147. 147.
    Turagam MK, Garg J, Whang W, et al. Catheter ablation of atrial fibrillation in patients with heart failure. A meta-analysis of randomized controlled trials. Ann Intern Med. 2019;170:41–50.PubMedGoogle Scholar
  148. 148.
    Reddy VY, Neuzil P, Koruth JS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74:315–26.PubMedGoogle Scholar
  149. 149.
    Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31.PubMedGoogle Scholar
  150. 150.
    Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality–clinical implications. Technol Cancer Res Treat. 2007;6:37–48.PubMedGoogle Scholar
  151. 151.
    Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng. 2006;53:1409–15.PubMedGoogle Scholar
  152. 152.
    Kotnik T, Kramar P, Pucihar G, Miklavcic D, Tarek M. Cell membrane electroporation—part 1: the phenomenon. IEEE Electr Insul. 2012;28:14–23.Google Scholar
  153. 153.
    Waks JW, Josephson ME. Mechanisms of atrial fibrillation – reentry, rotors and reality. Arrhythm Electrophysiol Rev. 2014;3(2):90–100.PubMedPubMedCentralGoogle Scholar
  154. 154.
    Narayan SM, et al. Treatment of atrial fibrillation by the ablation of localized sources CONFIRM (Conventional Ablation for Atrial Fibrillation with or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol. 2012;60(2):628–35.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Icahn School of MedicineMount Sinai HospitalNew YorkUSA

Personalised recommendations